<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797662</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-116</org_study_id>
    <secondary_id>UM1CA121947</secondary_id>
    <nct_id>NCT05797662</nct_id>
  </id_info>
  <brief_title>A Study of Propranolol to Treat Kaposi Sarcoma</brief_title>
  <official_title>A Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Children and Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIDS Malignancy Consortium</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>AIDS Malignancy Consortium</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study of propranolol for the treatment of Kaposi Sarcoma in children and adults.&#xD;
      This study will be an open-label single armed treatment trial that will test the&#xD;
      effectiveness and the safety of treating Kaposi Sarcoma with propranolol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible study participants will receive propanolol twice daily for an initial 12-week&#xD;
      period. At the conclusion of 12-weeks, response will be assessed. Participants who achieve a&#xD;
      complete or partial response will continue propanolol for an additional 6 weeks or 12 weeks,&#xD;
      respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2024</start_date>
  <completion_date type="Anticipated">August 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>At one year</time_frame>
    <description>ORR is defined as the proportion of participants with complete response (CR), or partial response (PR) based on AIDS Malignancy Consortium Kaposi Sarcoma (AMC KS) Response Criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of dose-limiting toxicities</measure>
    <time_frame>At one year</time_frame>
    <description>To evaluate the number of dose-limiting toxicities. The dose-limiting toxicities will be based on the National Cancer Institute's Common Terminology Criteria for Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-emergent adverse events</measure>
    <time_frame>At one year</time_frame>
    <description>To evaluate the number of treatment-emergent adverse events. The treatment-emergent adverse events will be based on the National Cancer Institute's Common Terminology Criteria for Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete and Partial Response rates in children and adults</measure>
    <time_frame>At one year</time_frame>
    <description>Proportion of children and adults with a Complete Response or Partial Response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence among children</measure>
    <time_frame>At one year</time_frame>
    <description>Time to recurrence among responders overall in children. Recurrent disease is defined as the appearance of tumor following documentation of a complete remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence among adults</measure>
    <time_frame>At one year</time_frame>
    <description>Time to recurrence among responders overall in adults. Recurrent disease is defined as the appearance of tumor following documentation of a complete remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression among children</measure>
    <time_frame>At one year</time_frame>
    <description>Time to progression among responders overall in children. Time to progression is defined as time from initiation of propranolol to documentation of first progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression among adults</measure>
    <time_frame>At one year</time_frame>
    <description>Time to progression among responders overall in adults. Time to progression is defined as time from initiation of propranolol to documentation of first progression.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Kaposi Sarcoma</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Propranolol Twice Daily (BID) x 12 weeks Dosage: For ages ≤ 12 years: 3mg/kg/day divided BID; for ages &gt; 12 years, 120 mg BID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pediatric (&lt; 18 years) and adult (≥ 18 years) participants with biopsy-proven and&#xD;
             measurable Kaposi Sarcoma (KS) as defined in the KS Manual of Procedures (MOP).&#xD;
&#xD;
          -  No urgent clinical indication for immediate cytotoxic chemotherapy. Participants who&#xD;
             have received cytotoxic chemotherapy &gt; 4 weeks prior to screening are eligible.&#xD;
&#xD;
          -  KS stage:&#xD;
&#xD;
               -  &lt; 18 years:&#xD;
&#xD;
                    -  1A (Mild): disease limited to skin, flat oral mucosal lesions, and/or flesh&#xD;
                       colored subcutaneous nodules, total &lt;10 lesions.&#xD;
&#xD;
                    -  1B (Moderate): having any of the following features, alone or in&#xD;
                       combination: a total of 10-19 hyperpigmented skin/oral lesions, nodular oral&#xD;
                       involvement, conjunctival eye involvement, or exophytic mass.&#xD;
&#xD;
               -  ≥ 18 years:&#xD;
&#xD;
                    -  T0: confined to skin and/or lymph nodes and/or minimal oral lesions.&#xD;
&#xD;
                    -  T1: limited to tumor-associated edema of cutaneous lesions without&#xD;
                       functional impairment or flat oral lesions.&#xD;
&#xD;
          -  Performance Status:&#xD;
&#xD;
               -  &lt; 18 years:&#xD;
&#xD;
                    -  Lansky performance status &gt; 70%&#xD;
&#xD;
               -  ≥ 18 years:&#xD;
&#xD;
                    -  Easter Cooperative Oncology Group (ECOG) performance status ≤ 2&#xD;
&#xD;
          -  Participants must have adequate organ function, as defined by the following:&#xD;
&#xD;
               -  Bilirubin (direct or total) within normal range, or total bilirubin &lt;3.0 mg/dl&#xD;
                  for participants with Gilbert syndrome.&#xD;
&#xD;
               -  Calculated creatinine clearance ≥ 30 mL/min for participants ≥ 12 years (see&#xD;
                  Appendix III); creatinine &lt;1.5 Upper Limit Normal (ULN) for participants &lt; 12&#xD;
                  years.&#xD;
&#xD;
               -  Hemoglobin &gt; 9 g/dL;&#xD;
&#xD;
               -  Platelets &gt; 100 × 109/L;&#xD;
&#xD;
               -  ANC &gt; 1000 cells/mm3&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV) positive participants must be on antiretroviral&#xD;
             therapy (ART) that conforms to local standards of care. Participants will have been on&#xD;
             ART for at least 12 weeks. Participants will not be excluded based on CD4 count or HIV&#xD;
             viral load.&#xD;
&#xD;
          -  HIV positive participants must not show recent improvement on ART that may confound&#xD;
             response evaluation:&#xD;
&#xD;
               -  If on ART 12 to 24 weeks, participants must show evidence of KS progression&#xD;
                  requiring further systemic treatment.&#xD;
&#xD;
               -  If on ART for &gt;24 weeks, must show no evidence of regression in the last eight&#xD;
                  weeks.&#xD;
&#xD;
          -  HIV-negative participants must not show evidence of improvement in the three months&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  No history of asthma or diabetes mellitus (as it is a risk factor for hypoglycemia).&#xD;
&#xD;
          -  No clinically significant cardiovascular disease other than hypertension, which is&#xD;
             permitted.&#xD;
&#xD;
          -  No use of beta-adrenergic antagonists for other indications.&#xD;
&#xD;
          -  Not pregnant or planning to become pregnant. Propranolol is United Stats Food and Drug&#xD;
             Administration (US FDA) pregnancy category C. At this time, the study team has&#xD;
             determined that the unknown risk to a developing fetus is greater than the potential&#xD;
             benefit of treatment.&#xD;
&#xD;
          -  Use of effective contraception for women of childbearing potential, defined as a&#xD;
             sexually mature woman who: 1) has not undergone a hysterectomy or bilateral&#xD;
             oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive&#xD;
             months.&#xD;
&#xD;
          -  Women of child bearing potential (WOCBP) must agree to use adequate contraception&#xD;
             (oral contraceptive pills, intrauterine device, Nexplanon, Depo-Provera, or permanent&#xD;
             sterilization, etc., or another acceptable method as determined by the investigator)&#xD;
             prior to study entry, for the duration of study participation.&#xD;
&#xD;
          -  Not breast feeding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Participants who do not fulfill the criteria as listed in Section 3.1 above, are&#xD;
        ineligible. Additionally, the presence of any of the following conditions will exclude a&#xD;
        participant from study enrollment:&#xD;
&#xD;
          -  Children and adolescents with lymph node or visceral disease, woody edema, or ≥ 20&#xD;
             cutaneous lesions.&#xD;
&#xD;
          -  Children and adolescents with heart rate or systolic blood pressure &lt;10th percentile&#xD;
             for age.&#xD;
&#xD;
          -  Adults with visceral disease or tumor-associated edema causing functional impairment.&#xD;
&#xD;
          -  Shortness of breath, hemoptysis, or moderate/severe cough not attributable to causes&#xD;
             other than KS.&#xD;
&#xD;
          -  Bleeding from the mouth or rectum not attributable to causes other than KS.&#xD;
&#xD;
          -  Treatment for active and serious infection.&#xD;
&#xD;
          -  Children with severe acute malnutrition based on World Health Organization (WHO)&#xD;
             criteria (Mid-upper arm circumference &lt;11.5 cm, weight-for height Z-score &lt;-3 or&#xD;
             presence of symmetrical pitting edema).&#xD;
&#xD;
          -  Given the risk of hypotension and hypoglycemia, participants must take the study drug&#xD;
             with food. If needed, the study team will pursue additional funding to support&#xD;
             providing supplemental food for participants who experience food insecurity.&#xD;
&#xD;
          -  Patients who experienced hypersensitivity to propranolol during initiation phase of&#xD;
             treatment or had previous known allergy to propranolol or allergy to other β-blockers.&#xD;
&#xD;
          -  Patients with a history of uncompensated heart failure; severe sinus bradycardia; sick&#xD;
             sinus syndrome; or heart block greater than first-degree.&#xD;
&#xD;
          -  Patients with diagnosed obstructive airway disease such as asthma, chronic obstructive&#xD;
             pulmonary disease (COPD), or bronchiolitis.&#xD;
&#xD;
          -  History of diabetes mellitus (as it is a risk factor for hypoglycemia)&#xD;
&#xD;
          -  Patients receiving concurrent treatment with an anticancer therapy. Patients must not&#xD;
             have received any anticancer therapies within 30 days prior to receiving the first&#xD;
             dose of investigational treatment.&#xD;
&#xD;
          -  Patients with concern for Kaposi Sarcoma herpesvirus (KSHV) inflammatory cytokine&#xD;
             syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shane McAllister, Md, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Minnesota Medical School Department of Pediatrics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shane McAllister, Md, Phd</last_name>
    <phone>612-301-2205</phone>
    <email>smcallis@umn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundación Huésped</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <contact>
      <last_name>Pedro Cahn, PhD</last_name>
      <phone>54 (11) 4981-7777</phone>
      <email>pedro.cahn@huesped.org.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Câncer José de Alencar</name>
      <address>
        <city>Rio De Janeiro</city>
        <zip>20231-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabio Leal, MD, PhD</last_name>
      <phone>552132076557</phone>
      <email>fabio.leal@inca.gov.br</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalar Universitário Professor Edgard Santos</name>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
    <contact>
      <last_name>Carlos Brites, PhD</last_name>
      <phone>55 (71) 3283-8123</phone>
      <email>crbrites@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moi University School of Medicine</name>
      <address>
        <city>Eldoret</city>
        <country>Kenya</country>
      </address>
    </facility>
    <contact>
      <last_name>Naftali Busakhala</last_name>
      <phone>254-722-496-933</phone>
      <email>nbusakhala@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Naftali Busakhala, MBChB MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Project Malawi</name>
      <address>
        <city>Lilongwe</city>
        <country>Malawi</country>
      </address>
    </facility>
    <contact>
      <last_name>Lameck Chinula</last_name>
      <phone>265 88 248 3220</phone>
      <email>lchinula@unclilongwe.org</email>
    </contact>
    <investigator>
      <last_name>Lameck Chinula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancerologia</name>
      <address>
        <city>Ciudad de Mexico</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Patricia Volkow, MD</last_name>
      <phone>5255 51026450</phone>
      <email>pvolkowf@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Patricia Volkow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>African Cancer Institute at Stellenbosch</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Hennie Botha, MMed PhD</last_name>
      <phone>+27 (21) 938-9209</phone>
      <email>mhbotha@sun.ac.za</email>
    </contact>
    <investigator>
      <last_name>Hennie Botha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uganda Cancer Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <contact>
      <last_name>Jackson Orem, MD</last_name>
      <phone>+256 414540 410</phone>
      <email>jacksonorem@yahoo.co.uk</email>
    </contact>
    <investigator>
      <last_name>Jackson Orem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe College of Health Sciences</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
    <contact>
      <last_name>Margaret Borok, MBChB, FRCP</last_name>
      <phone>+263 (242) 791-631</phone>
      <email>mborok@mweb.co.zw</email>
    </contact>
    <investigator>
      <last_name>Margaret Borok, MBChB (Hons) FRCP(UK)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>Mexico</country>
    <country>South Africa</country>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 13, 2023</last_update_submitted>
  <last_update_submitted_qc>April 13, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kaposi Sarcoma</keyword>
  <keyword>Propranolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

